This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Ninlaro click here.

NICE recommendation

Ninlaro (ixazomib) is now
recommended by NICE via the CDF:

NINLARO (ixazomib) with lenalidomide and dexamethasone (Rd) is recommended for use within the Cancer Drugs Fund (CDF) as an option for treating multiple myeloma (MM) in adults if they have already had 2 or 3 previous lines of therapy and the conditions of the managed access agreement for ixazomib are followed7

7. NICE Final Appraisal Determination - Ixazomib, with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
https://www.nice.org.uk/guidance/indevelopment/gid-ta10043 Accessed December 2017

Close this message
NINLARO ixazomib capsules

Extended Efficacy.
Extended Possibilities.

NINLARO (ixazomib) + Rd significantly extends PFS vs Rd alone and offers
a manageable side effect profile with the convenience of an all-oral regimen1,2

NINLARO: the first and only oral proteasome inhibitor licensed in combination with lenalidomide and dexamethasone (Rd) for treatment of adult patients with multiple myeloma who have received at least 1 prior therapy2

Adding oral NINLARO to Rd extends PFS across a broad group of patients compared with Rd alone1,2

A long-term treatment approach in RRMM should address efficacy, tolerability and patient burden.3 However, long-term treatment in MM remains a challenge with a number of current therapeutic options.4 Adding oral NINLARO to Rd extends PFS across a broad group of patients irrespective of cytogenetic risk, compared with Rd alone.1

Patient support

Takeda Oncology has developed a range of information and support tools designed for patients prescribed NINLARO

Click here to find out more about the support offered to NINLARO patients